Mode
Text Size
Log in / Sign up

Robotic-assisted endoscopic submucosal dissection achieves 98.2% en-bloc and 96.8% R0 resection rates in GI neoplasmsRobotic surgery shows high success for removing gastrointestinal tumors

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that R-ESD shows high resection rates for GI neoplasms, but evidence is limited by small, non-comparative studies.

This Bayesian single-arm meta-analysis evaluated the efficacy and safety of robotic-assisted endoscopic submucosal dissection (R-ESD) for the treatment of superficial gastrointestinal (GI) neoplasms. The analysis pooled data from 5 studies involving 183 lesions to assess primary outcomes of en-bloc and R0 resection rates, alongside secondary outcomes including procedure time, perforation, and bleeding.

Frequentist analysis reported an en-bloc resection rate of 98.2% (95% CI: 0.916-0.996) and an R0 resection rate of 96.8% (95% CI: 0.759-0.997). Bayesian median estimates for these outcomes were 93.4% (95% CrI: 0.856-0.971) and 90.0% (95% CrI: 0.798-0.957), respectively. Secondary outcomes included a mean procedure time of 77.6 minutes (95% CI: 45.0-110.3), a perforation rate of 1.2% (95% CI: 0.002-0.077), and a bleeding rate of 10.6% (95% CI: 0.019-0.416).

The authors note that the evidence is limited by the use of small, mostly non-comparative studies. While R-ESD shows promising efficacy and safety for superficial GI neoplasms, the low certainty of the data means larger comparative trials are required before definitive conclusions can be reached regarding its clinical superiority or definitive safety profile.

When doctors remove tumors from the digestive tract, the goal is to remove the entire growth in one piece. This is called an en-bloc resection. Doing this correctly is vital because it helps ensure no cancer cells are left behind. A recent look at data from 183 lesions shows that robotic-assisted endoscopic submucosal dissection (R-ESD) achieved an en-bloc resection rate of 98.2%.

In addition to removing the tumor in one piece, the procedure aimed for an R0 resection, which means no visible cancer remains at the edges. The study found a 96.8% success rate for this goal. While the procedure took an average of about 78 minutes, safety signals were generally low. The rate of perforation, or a hole in the organ, was 1.2%, and the rate of bleeding was 10.6%.

It is important to keep these findings in perspective. Because the data comes from a small number of studies that did not compare the robot to other methods, the evidence is currently considered limited. While the results for R-ESD are promising, larger trials are needed to confirm exactly how it compares to standard treatments.

What this means for you:
Robotic-assisted surgery shows high success in removing gastrointestinal tumors, but more large trials are needed.

Common questions

How successful is robotic surgery for removing gastrointestinal tumors?

The study found a 98.2% en-bloc resection rate, which means the tumor was removed in one piece. Additionally, the rate for an R0 resection, where no cancer remains at the edges, was 96.8%.

What are the risks of this procedure?

The procedure showed a 1.2% rate of perforation, which is a hole in the organ, and a 10.6% rate of bleeding. These figures were based on 183 lesions across five different studies.

Is this a proven treatment for everyone?

The results are promising, but the evidence is currently limited because the data comes from small, non-comparative studies. Larger trials are needed before definitive conclusions can be made about its use.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
Superficial gastrointestinal (GI) neoplasms pose a significant global health burden, with endoscopic submucosal dissection (ESD) as the gold standard for curative resection. However, conventional ESD (C-ESD) is technically challenging, with prolonged procedure times and higher complication risks. Robotic-assisted ESD (R-ESD) offers enhanced precision and safety, but evidence is limited. To evaluate the efficacy and safety of R-ESD using a Bayesian single-arm Meta-analysis. Systematic review and Bayesian single-arm meta-analysis. Following PRISMA guidelines and PROSPERO registration (CRD420251273787), we conducted a systematic review and Bayesian single-arm meta-analysis of randomized/nonrandomized comparative and single-arm studies on R-ESD for superficial GI neoplasms. Searches spanned MEDLINE, Embase, Scopus, and others through December 2025. Primary outcomes: en-bloc and R0 resection rates. Secondary outcomes: procedure time, perforation, bleeding. Bayesian random-effects models used non-informative priors; analyses in R with the brms package. Risk of bias was assessed via RoB 2 and NOS; certainty via GRADE. Five studies (183 lesions) were included. Frequentist pooled en-bloc resection rate: 98.2% (95% CI: 0.916-0.996, I2 = 0%); R0: 96.8% (95% CI: 0.759-0.997, I2 = 47.8%). Bayesian medians: en-bloc 93.4% (95% CrI: 0.856-0.971); R0 90.0% (95% CrI: 0.798-0.957). 77.6 min (95% CI: 45.0-110.3, I2 = 99%); perforation: 1.2% (95% CI: 0.002-0.077, I2 = 0%); bleeding: 10.6% (95% CI: 0.019-0.416, I2 = 30.8%). Evidence certainty:low. R-ESD demonstrates promising efficacy and safety, but current evidence is limited to small, mostly non-comparative studies. Larger comparative trials are required before definitive conclusions can be made.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.